Global CFTR Modulators Market Report 2021 - Trikafta will Dominate the Market with 50% Market Share in 2020 and Sales of $5 Billion by 2026

News provided by

May 07, 2021, 13:15 ET

DUBLIN, May 7, 2021 /PRNewswire/ -- The "Global CFTR Modulators Market Opportunity, Dosage, Price & Clinical Trials Insight 2026" report has been added to ResearchAndMarkets.com's offering.

"Global CFTR Modulators Market Opportunity, Dosage, Price & Clinical Trials Insight 2026" provides comprehensive insight on clinical and non-clinical factors that are driving the global CFTR Modulators market and its impact on the global pharmaceutical market landscape.

The report has been prepared in a view to deeply profile the current market trends along with the sales insight on 4 commercially available CFTR Modulators with their, market share and the clinical profile.

The advent of CFTR modulators in the management of cystic fibrosis has greatly transformed the overall market. Cystic fibrosis transmembrane conductance regulator (CFTR) modulator therapies are targeted drugs which have been developed by the researchers to correct the malfunctioning protein made by the CFTR gene. Because different mutations cause different defects in the protein, the medications that have been developed so far are effective only in people with specific mutations.

Currently, four CFTR Modulators have been approved for the management of cystic fibrosis. Among them, Trikafta developed by Vertex Pharmaceuticals is the first triple combination therapy available to treat patients who have at least one F508del mutation in the cystic fibrosis transmembrane conductance regulator (CFTR) gene, which is estimated to represent 90% of the cystic fibrosis population. This drug has shown high clinical response and has significantly enhanced the median survival rates in patients.

Trikafta was recently granted approval in late 2019 and within short span of time, the drug has dominated the overall CFTR modulator drug market. As of 2020, the novel drug Trikafta have sales of more than US$ 3 Billion which is expected to rise at high rates to reach about US$ 5 Billion by 2026. The high market size of the drug is mainly attributed to the increase in prevalence of the disease and the unmet need of combinational therapy in management of them. Moreover, the high adoption rate of this drug is due to its ability to enhance the median survival rates in patients.

The elexacaftor and tezacaftor contained in TRIKAFTA bind to the CFTR protein and facilitate the cellular processing of F508del-CFTR. The combination helps in increasing the amount of CFTR protein delivered to the cell surface, while ivacaftor aids in the gating of the CFTR protein at the cell surface. The combined effect of the three drugs boosts the amount and function of F508del-CFTR at the cell surface. The targeted nature of drug in the management of cystic fibrosis also aids in boosting the growth of CFTR modulator drugs market.

US is currently dominating the market and is expected to do so for next few years. This is mainly due to the rising Caucasian population in the region which has maximum risk of developing the disease. In addition to this, the high adoption rates of novel therapy as well as rising initiative by government to initiate research and development activities will also drive the future of the market. In addition to this, Europe and Asia are also competing to occupy a considerable position in the market by investing a huge amount in research and development.

It is expected that the drug Trikafta will dominate the market for next few years which is due to its triple combination which have better ability to tackle the complexity of cystic fibrosis disease. The overall CFTR modulator market will also witness high growth rates and rapid approval of several other modulators which are currently under clinical trials. It is expected that CFTR modulator drugs will emerge as a potential drugs in the management of cystic fibrosis in coming years.

"Global CFTR Modulators Market Opportunity, Dosage, Price & Clinical Trials Insight 2026" Report Highlights:

Global CFTR Modulators Market Opportunity: > US$ 20 Billion
Global CFTR Modulators Market Growth: 42% CAGR (2017 -2020)
Global CFTR Modulators Market Growth In 2020: 55%
Global CFTR Modulators Pipeline: >30 Drug
Commercially Available CFTR Modulators: 4 Drugs
Trikafta Market Share 2020: > 50%

Key Topics Covered:

1. Introduction to CFTR Modulators
1.1 Overview
1.2 Evolution of CFTR Modulators

2. CFTR Modulators Mechanism of Action

3. Global CFTR Modulator Market Overview
3.1 Current Market Scenario
3.2 Future Market Potential of CFTR Modulators

4. US CFTR Modulator Market Overview
4.1 Current Market Scenario
4.2 Future Market Potential of CFTR Modulators

5. ROW CFTR Modulator Market Overview
5.1 Current Market Scenario
5.2 Future Market Potential of CFTR Modulators

6. Ivacaftor (Kalydeco) - Clinical & Commercial Insight
6.1 Overview
6.2 Patents & Assignees
6.3 Price & Dosage Insight
6.4 Sales Analysis

7. Ivacaftor/Lumacaftor (Orkambi) - Clinical & Commercial Insight
7.1 Overview
7.2 Patents & Assignees
7.3 Price & Dosage Insight
7.4 Sales Analysis

8. Tezacaftor/Ivacaftor (Symdeko) - Clinical & Commercial Insight
8.1 Overview
8.2 Patent & Assignees
8.3 Price & Dosage Insight
8.4 Sales

9. Elexacaftor/Ivacaftor/Tezacaftor (Trikafta) - Clinical & Commercial Insight
9.1 Overview
9.2 Patent & Assignees
9.3 Price & Dosage Insight
9.4 Global Sales

10. Global CFTR Modulators Vaccine Pipeline Overview
10.1 By Country
10.2 By Company
10.3 By Patient Segment
10.4 By Phase

11. Global CFTR Modulators Clinical Trials Insight
11.1 Research
11.2 Preclinical
11.3 Phase-I
11.4 Phase-I/II
11.5 Phase-II
11.6 Phase-III

12. Marketed CFTR Modulators Clinical Insights

13. CFTR Modulator Drugs Market Dynamics
13.1 Favorable Parameters
13.2 Market Restraints

14. CFTR Modulator Market Future Perspective

15. Competitive Landscape
15.1 Vertex Pharmaceuticals
15.2 Eloxx Pharma
15.3 ReCode Therapeutics
15.4 Arcturus Therapeutics
15.5 AbbVie
15.6 Spirovant Sciences
15.7 Translate Bio
15.8 ReAlta Life Sciences
15.9 Southern Research Institute
15.10 4D Molecular Therapeutics

For more information about this report visit https://www.researchandmarkets.com/r/j5pjf0

Media Contact:

Research and Markets
Laura Wood, Senior Manager
[email protected]

For E.S.T Office Hours Call +1-917-300-0470
For U.S./CAN Toll Free Call +1-800-526-8630
For GMT Office Hours Call +353-1-416-8900

U.S. Fax: 646-607-1907
Fax (outside U.S.): +353-1-481-1716

SOURCE Research and Markets